Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuron Biotech has started Phase 3 study of its NU100 to treat relapsing remitting multiple sclerosis (RRMS).
Subscribe to our email newsletter
NU100 is a proprietary recombinant human interferon beta-1b (IFN beta-1b) which utilizes the company’s refolding process technology being developed as a new molecular entity.
The double-blind, placebo-controlled, randomized trial is designed to assess the safety and efficacy of NU100.
The company is enrolling 500 patients from125 clinical sites across Europe and Asia.
The trial will randomize patients to receive NU100 or placebo and will be treated over a 12-month period.
Nuron Biotech Clinical and Medical Affairs vice president Tracy Goeken said they expect data from this study in late 2013.